Comparing potential benefits of new pneumococcal vaccines with the current polysaccharide vaccine in the elderly

Vaccine. 2002 Dec 13;21(3-4):303-11. doi: 10.1016/s0264-410x(02)00451-6.

Abstract

We compared the hypothetical effects of the 23-valent polysaccharide pneumococcal vaccine with new vaccines on preventing invasive and noninvasive pneumococcal disease in persons >or=65 years. We estimated how much disease would occur if no polysaccharide vaccine were in use and used this baseline to compare the polysaccharide, a 7-valent conjugate vaccine, and hypothetical common antigen vaccine. The polysaccharide, conjugate, and common antigen vaccines prevented 10.6, 10.7, and 17.7% of invasive disease and 4.3, 5.6, and 10.0% of pneumonia, respectively. Superior effectiveness of new vaccines was dependent upon a presumed longer duration of protection than the 23V-PPV and effectiveness against noninvasive pneumonia. Our results suggest that new vaccines could improve disease prevention.

Publication types

  • Comparative Study

MeSH terms

  • Aged
  • Aged, 80 and over
  • Aging / physiology
  • Bacterial Outer Membrane Proteins / chemistry
  • Bacterial Outer Membrane Proteins / immunology
  • Female
  • Humans
  • Male
  • Pneumococcal Infections / immunology
  • Pneumococcal Infections / mortality
  • Pneumococcal Infections / prevention & control*
  • Pneumococcal Vaccines / administration & dosage*
  • Pneumococcal Vaccines / immunology
  • Polysaccharides, Bacterial / administration & dosage*
  • Polysaccharides, Bacterial / chemistry
  • Polysaccharides, Bacterial / immunology
  • Sensitivity and Specificity
  • Streptococcus pneumoniae / immunology
  • Survival Analysis
  • Treatment Outcome
  • Vaccines, Conjugate / administration & dosage
  • Vaccines, Conjugate / chemistry
  • Vaccines, Conjugate / immunology

Substances

  • Bacterial Outer Membrane Proteins
  • Pneumococcal Vaccines
  • Polysaccharides, Bacterial
  • Vaccines, Conjugate